Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rilparencel - inRegen

Next Previous
Drug Profile

Rilparencel - inRegen

Alternative Names: Autologous cultured kidney tissue cells - inRegen; Autologous cultured kidney tissue cells - Tengion; Autologous Neo-Kidney augment; Neo-Kidney Augment; Neo-kidney-augment; NKA; ReACT; REACT™; Regenerative autologous cell therapy; Renal Autologous Cell Therapy

Latest Information Update: 17 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tengion
  • Developer inRegen; ProKidney
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Kidney disorders; Type 2 diabetes mellitus
  • No development reported Renal failure

Most Recent Events

  • 16 Jul 2025 ProKidney completes Type B meeting with US FDA to confirm the use of eGFR slope as the surrogate endpoint for accelerated approval of rilparencel
  • 08 Jul 2025 Efficacy and adverse event data from a phase II REGEN-007 trial in Kidney disorders released by ProKidney
  • 20 May 2025 Prokidney completes a phase II trial for Kidney disorders (In adults, In the elderly) in USA (Transdermal) (NCT05018416)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top